NCT05597202

Does the Hematopoietic Stem Cell Govern Residual Inflammatory Cardiovascular Risk in Type 2 Diabetes

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 22 (estimated)
• Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Academic / Other
• Sex: All
• Age: 50 Years
• Healthy volunteers: Not accepted

Summary

To study the effect of type 2 diabetes (T2D) on vascular wall inflammation and hematopoietic stem cell composition in vivo, and whether these changes can be reversed with glucagon like peptide 1 receptor (GLP1R)-agonism.

Detailed description

We will use 68Ga-Dotatate PET/CT scans, bone marrow aspirations and peripheral blood analyses to determine the effect of type 2 diabetes on vascular wall inflammation, and hematopoietic stem cell composition, and whether these changes can be reversed using high dose semaglutide treatment, up to 2.0mg subcutaneously per week, for a period of six months.

Conditions

• Type 2 Diabetes

Interventions

Type	Name	Description
DRUG	Semaglutide, 2.0 mg/mL	Semaglutide 2.0 mg/mL, administered subcutaneously once per week for a period of 6 months.

Timeline

• Start date: 2023-01-01
• Primary completion: 2024-03-01
• Completion: 2024-04-01
• First posted: 2022-10-27
• Last updated: 2023-05-09

Locations

1 site across 1 country: Netherlands